Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present application relates to compounds corresponding to the general formula (I)
• R- L represents a hydrogen atom, a group (C 1 -C 6 ) alkyl or a phenyl group (C x -C 4 ) alkyl optionally substituted
• R 2 represents a hydrogen atom or a group (Ci-Cg ) alkyl
• R 3 , R 4 and R 5 each represent, independently of one another, a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxy, (Cx-Cg) alkyl or (C- L - Cg) alkoxy.
• the two carbon atoms by which the pyrrolidine ring and the furo [3, 2 -jb] pyridine ring are linked are asymmetric; a compound according to the invention can therefore exist in the form of a pure optical isomer (R, R), (R, S), (S, R) or (S, S) or a mixture of such isomers.
• a compound according to the invention can also exist in the form of a free base or an addition salt with an acid.
• R x and R 2 each represent a hydrogen atom or an alkyl group, preferably a methyl group
• R 3 , R 4 and R 5 each represent a hydrogen or halogen atom , preferably chlorine, or a (C- L -C ⁇ alkyl, preferably methyl, or (C 1 -C 4 ) alkoxy, preferably methoxy group.
• the compounds of general formula (I) can be prepared by a process illustrated by the scheme above.
• a nitrogen alkylation of the pyrrolidine ring is carried out by any known method, for example methylation according to the method Eschweiler-Clarke (formaldehyde and formic acid) or by a reductive amination in the presence of an aldehyde and sodium cyanoborohydride, or alternatively an acylation, to form an amide, followed by a reduction in the presence of a reducing agent such than 1 double hydride of lithium and aluminum.
• the 2-halogenpyridin-3-ols are commercially available or can be prepared according to any method known to those skilled in the art.
• the (S) - and (R) -2-ethynylpyrrolidine-l-carboxylate of 1,1-dimethylethyl can be prepared from proline (S) or (j) by the method of Corey-Fuchs, described in Tetrahedron Letters (1990) 31 (28) 3957-3960.
• Example 1 (Compounds No. 1 and 2).
• Extraction is carried out with dichloromethane to obtain the crude product in the form of an oil, which is purified by chromatography on silica gel, eluting with a 95/5 / 0.5 mixture of dichloromethane, ethanol and ammonia, to obtain the pure product. in basic form.
• the hydrochloride is formed by addition of hydrochloric acid in ethanol.
• the solvent is evaporated off under reduced pressure and the medium is made alkaline by the addition of concentrated ammonia.
• the tissue is thawed slowly and suspended in 3 volumes of buffer. 150 ⁇ l of this membrane suspension are incubated at 4 ° C. for 120 min in the presence of 100 ⁇ l of [ 3 H] 1 nM cytisine in a final volume of 500 ⁇ l of buffer, in the presence or absence of the compound to be tested.
• the reaction is stopped by filtration on hatman GF / B TM filters previously treated with polyethyleneimine, the filters are rinsed with twice 5 ml of buffer at 4 ° C., and the radioactivity retained on the filter is measured by liquid scintigraphy.
• the non-specific binding is determined in the presence of (-) -nicotine at 10 ⁇ M; non-specific binding represents 75 to 85% of the total binding recovered on the filter.
• the percentage of inhibition of the specific binding of [ 3 H] cytisine is determined, then the IC 50 , the concentration of compound which inhibits 50% of the specific binding, is calculated.
• the IC 50 values of the compounds of the invention are between 0.01 and 100 ⁇ M.
• the results of biological tests carried out on the compounds of the invention show that they are powerful and selective cholinergic ligands for nicotinic receptors.
• these disorders include cognitive alterations, more specifically memory impairment, but also attentional alterations, linked to Alzheimer's disease, to pathological aging (Age Associated Memory Impairment, AAMI), to Parkinson's syndrome, to trisomy 21 ( Down's syndrome), alcoholic Korsakoff syndrome, vascular dementia (multi-infarct dementia, MID).
• AAMI Alzheimer's disease
• AAMI pathological aging
• Parkinson's syndrome to Parkinson's syndrome
• trisomy 21 Down's syndrome
• alcoholic Korsakoff syndrome vascular dementia (multi-infarct dementia, MID).
• vascular dementia multi-infarct dementia
• MID multi-infarct dementia
• the compounds of the invention can also constitute a curative or symptomatic treatment of cerebrovascular accidents and cerebral hypoxic episodes. They can be used in cases of psychiatric pathologies: schizophrenia, depression, anxiety, panic attacks, compulsive and obsessive behaviors.
• the compounds of the invention could be useful in the treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome and obesity.
• compositions suitable for enteral, parenteral or transdermal administration such as tablets, dragees, capsules, capsules, suspensions or oral or injectable solutions such as syrups or ampoules, transdermal patches ("patch"), etc., associated with suitable excipients, and dosed to allow daily administration of 0.01 to 20 mg / kg.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9505006

Family Applications (1)

Country Status (22)

Families Citing this family (9)

Family Cites Families (1)

• 1997
  • 1997-03-20 FR FR9703395A patent/FR2761072B1/fr not_active Expired - Fee Related
• 1998
  • 1998-03-17 KR KR1019997008379A patent/KR20000076282A/ko not_active Application Discontinuation
  • 1998-03-17 PL PL98335759A patent/PL335759A1/xx unknown
  • 1998-03-17 CA CA002282320A patent/CA2282320A1/en not_active Abandoned
  • 1998-03-17 CN CN98803563A patent/CN1251105A/zh active Pending
  • 1998-03-17 IL IL13125498A patent/IL131254A0/xx unknown
  • 1998-03-17 SK SK1276-99A patent/SK127699A3/sk unknown
  • 1998-03-17 EP EP98914931A patent/EP0971929A1/fr not_active Withdrawn
  • 1998-03-17 NZ NZ337566A patent/NZ337566A/xx unknown
  • 1998-03-17 AU AU69242/98A patent/AU6924298A/en not_active Abandoned
  • 1998-03-17 HU HU0002335A patent/HUP0002335A3/hu unknown
  • 1998-03-17 US US09/381,098 patent/US6143761A/en not_active Expired - Fee Related
  • 1998-03-17 BR BR9808346-5A patent/BR9808346A/pt not_active IP Right Cessation
  • 1998-03-17 TR TR1999/02115T patent/TR199902115T2/xx unknown
  • 1998-03-17 WO PCT/FR1998/000531 patent/WO1998042713A1/fr not_active Application Discontinuation
  • 1998-03-17 EE EEP199900414A patent/EE9900414A/xx unknown
  • 1998-03-17 JP JP54444598A patent/JP2001518099A/ja active Pending
  • 1998-03-18 CO CO98015204A patent/CO4940417A1/es unknown
  • 1998-03-18 AR ARP980101212A patent/AR012097A1/es unknown
  • 1998-03-19 ZA ZA982365A patent/ZA982365B/xx unknown
• 1999
  • 1999-08-24 BG BG103684A patent/BG103684A/bg unknown
  • 1999-09-17 NO NO994527A patent/NO994527L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events